Arvinas (NASDAQ:ARVN) CFO Andrew Saik Sells 5,134 Shares of Stock

Arvinas, Inc. (NASDAQ:ARVN) CFO Andrew Saik sold 5,134 shares of the business’s stock in a transaction that occurred on Friday, February 13th. The shares were sold at an average price of $11.89, for a total value of $61,043.26. Following the completion of the sale, the chief financial officer owned 159,267 shares of the company’s stock, valued at $1,893,684.63. This trade represents a 3.12% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Arvinas Price Performance

Arvinas stock opened at $11.82 on Thursday. Arvinas, Inc. has a 12 month low of $5.90 and a 12 month high of $19.40. The company has a fifty day moving average price of $12.38 and a two-hundred day moving average price of $10.33. The company has a market cap of $759.08 million, a PE ratio of -14.59 and a beta of 1.88.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on ARVN. BTIG Research lifted their target price on Arvinas from $10.00 to $14.00 and gave the company a “buy” rating in a research note on Thursday, October 30th. Barclays upped their price target on Arvinas from $16.00 to $18.00 and gave the company an “overweight” rating in a report on Wednesday, December 17th. Citigroup raised shares of Arvinas from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $10.00 to $15.00 in a research report on Tuesday, January 6th. Wells Fargo & Company reduced their price target on shares of Arvinas from $16.00 to $15.00 and set an “overweight” rating for the company in a research report on Thursday, November 6th. Finally, Stephens lifted their price objective on shares of Arvinas from $14.00 to $15.00 and gave the stock an “overweight” rating in a research report on Monday, November 10th. Ten investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $13.12.

Arvinas News Roundup

Here are the key news stories impacting Arvinas this week:

• Positive Sentiment: Company webcast scheduled for Feb 24, 2026 to report Q4 and full‑year 2025 results and provide a corporate update — a clear near‑term catalyst that may drive volatility and give management a chance to reset expectations or highlight pipeline progress. Arvinas to Report Q4 and Full Year 2025 Financial Results
• Neutral Sentiment: Short‑interest data in recent reports shows 0 shares (days‑to‑cover 0.0), which appears to be a data anomaly and is unlikely to reflect meaningful changes in short positioning; treat the short‑interest figures with caution.
• Neutral Sentiment: Technical/market context — ARVN’s market cap is roughly $759M, the stock is trading below its 50‑day SMA (~$12.40) but above its 200‑day SMA (~$10.32). These levels matter for momentum/technical traders ahead of the earnings webcast.
• Negative Sentiment: Insider selling from multiple senior executives on Feb 13 — CEO Randy Teel (4,403 shares), CFO Andrew Saik (5,134 shares), CAO David K. Loomis (1,016 shares) and insider Noah Berkowitz (5,685 shares) sold stock at an average price of $11.89, each reducing their holdings roughly 2.8–3.4%. Clustered insider sales by top officers can pressure sentiment even if sizes are modest. SEC filings: CAO sale (Loomis Form 4), Noah Berkowitz sale (Berkowitz Form 4), Andrew Saik sale (Saik Form 4), Randy Teel sale (Teel Form 4).

Institutional Trading of Arvinas

Several hedge funds and other institutional investors have recently modified their holdings of ARVN. AQR Capital Management LLC purchased a new stake in shares of Arvinas during the 1st quarter worth about $727,000. Jacobs Levy Equity Management Inc. bought a new position in Arvinas during the first quarter valued at approximately $301,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Arvinas by 5.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,636 shares of the company’s stock valued at $271,000 after acquiring an additional 2,122 shares in the last quarter. Millennium Management LLC lifted its stake in Arvinas by 208.4% in the first quarter. Millennium Management LLC now owns 1,310,326 shares of the company’s stock valued at $9,198,000 after acquiring an additional 885,483 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Arvinas by 108.3% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 902,925 shares of the company’s stock valued at $6,339,000 after purchasing an additional 469,394 shares in the last quarter. 95.19% of the stock is currently owned by hedge funds and other institutional investors.

Arvinas Company Profile

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.